Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review

Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort

(2017) Minkyu Jung et al.   Cancer Research and Treatment

Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab

(2016) P. F. Ferrucci et al.   ANNALS OF ONCOLOGY

Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma

(2016) S Diem et al.   BRITISH JOURNAL OF CANCER

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

(2016) Willy Hugo et al.   CELL

Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

(2016) A. Martens et al.   CLINICAL CANCER RESEARCH

PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis

(2016) Sara Gandini et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab

(2016) Kilian Wistuba-Hamprecht et al.   EUROPEAN JOURNAL OF CANCER

Use of LDH and autoimmune side effects to predict response to ipilimumab treatment

(2016) J Dick et al.   Immunotherapy

Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry

(2016) Jinhyun Cho et al.   INVESTIGATIONAL NEW DRUGS

Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients

(2016) Teofila Seremet et al.   Journal of Translational Medicine

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

(2016) N. McGranahan et al.   SCIENCE

Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy

(2016) Douglas B. Johnson et al.   Nature Communications

Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

(2016) P.-L. Chen et al.   Cancer Discovery

Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab

(2016) J. Weber et al.   Cancer Immunology Research

Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab

(2016) Janet Retseck et al.   Journal for ImmunoTherapy of Cancer

Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients

(2015) P F Ferrucci et al.   BRITISH JOURNAL OF CANCER

High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma

(2015) J. Zaragoza et al.   BRITISH JOURNAL OF DERMATOLOGY

Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab

(2015) Y. Koguchi et al.   CANCER RESEARCH

Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25

(2015) Dalil Hannani et al.   CELL RESEARCH

Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab

(2015) C. Gebhardt et al.   CLINICAL CANCER RESEARCH

Recent developments and future challenges in immune checkpoint inhibitory cancer treatment

(2015) Bas D. Koster et al.   CURRENT OPINION IN ONCOLOGY

Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab

(2015) S. Valpione et al.   EUROPEAN JOURNAL OF CANCER

Prognostic score for patients with advanced melanoma treated with ipilimumab

(2015) Stefan Diem et al.   EUROPEAN JOURNAL OF CANCER

Ipilimumab in the real world

(2015) Saif S. Ahmad et al.   MELANOMA RESEARCH

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review

(2015) D. B. Johnson et al.   ONCOLOGIST

Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients

(2015) Emanuela Romano et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

(2015) E. M. Van Allen et al.   SCIENCE

Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma

(2015) LEILA KHOJA et al.   Oncology Letters

A novel immune resistance mechanism of melanoma cells controlled by the ADAR1 enzyme

(2015) Gilli Galore-Haskel et al.   Oncotarget

Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma

(2015) Elin S. Gray et al.   Oncotarget

Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice

(2015) Luís Felipe Campesato et al.   Oncotarget

Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies

(2015) D. B. Johnson et al.   Cancer Immunology Research

Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab

(2015) Jon Bjoern et al.   OncoImmunology

Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma

(2015) James Larkin et al.   JAMA Oncology

Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma

(2015) Michael A. Postow et al.   Journal for ImmunoTherapy of Cancer

Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma

(2015) Ahmad A. Tarhini et al.   Journal for ImmunoTherapy of Cancer

Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?

(2015) Joanna Mangana et al.   PLoS One

Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma

(2014) Sander Kelderman et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

(2014) Ester Simeone et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma

(2014) G. T. Gibney et al.   CLINICAL CANCER RESEARCH

Blood mRNA Expression Profiling Predicts Survival in Patients Treated with Tremelimumab

(2014) Y. Saenger et al.   CLINICAL CANCER RESEARCH

CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire

(2014) L. Robert et al.   CLINICAL CANCER RESEARCH

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma

(2014) Marliese Alexander et al.   MEDICAL JOURNAL OF AUSTRALIA

Ipilimumab for advanced melanoma

(2014) Alfonso Berrocal et al.   MELANOMA RESEARCH

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

(2014) Alexandra Snyder et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab

(2014) Ahmad A. Tarhini et al.   PLoS One

Pretreatment Serum VEGF Is Associated with Clinical Response and Overall Survival in Advanced Melanoma Patients Treated with Ipilimumab

(2014) J. Yuan et al.   Cancer Immunology Research

Computational Algorithm-Driven Evaluation of Monocytic Myeloid-Derived Suppressor Cell Frequency for Prediction of Clinical Outcomes

(2014) S. Kitano et al.   Cancer Immunology Research

Clinical Benefit from Ipilimumab Therapy in Melanoma Patients may be Associated with Serum CTLA4 Levels

(2014) Anna M. Leung et al.   Frontiers in Oncology

Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab

(2013) Christiane Meyer et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Association of CTLA-4 Polymorphisms with Improved Overall Survival in Melanoma Patients Treated with CTLA-4 Blockade: A Pilot Study

(2013) P. Queirolo et al.   CANCER INVESTIGATION

Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma

(2013) Nienke van Rooij et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma

(2013) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Single-Center Experience With Ipilimumab in an Expanded Access Program for Patients With Pretreated Advanced Melanoma

(2013) Sofie Wilgenhof et al.   JOURNAL OF IMMUNOTHERAPY

Natural Killer T Cells in Advanced Melanoma Patients Treated with Tremelimumab

(2013) F. Javier Ibarrondo et al.   PLoS One

Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab

(2012) Vafa Shahabi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Biomarkers on melanoma patient T Cells associated with ipilimumab treatment

(2012) Wenshi Wang et al.   Journal of Translational Medicine

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

An immune-active tumor microenvironment favors clinical response to ipilimumab

(2011) Rui-Ru Ji et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

(2011) Omid Hamid et al.   Journal of Translational Medicine

Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab

(2011) J. Yuan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting

(2010) Geoffrey Y. Ku et al.   CANCER

Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma

(2010) A. A. Sarnaik et al.   CLINICAL CANCER RESEARCH

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

(2010) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma

(2009) A. Ribas et al.   CLINICAL CANCER RESEARCH

Influence of Cytotoxic T Lymphocyte-associated Antigen 4 (CTLA4) Common Polymorphisms on Outcome in Treatment of Melanoma Patients With CTLA-4 Blockade

(2009) Willemijn B. Breunis et al.   JOURNAL OF IMMUNOTHERAPY